Interventional, Randomized, Double-blind, Sequential-group, Placebo-controlled, Single-ascending-dose Study Investigating the Safety, Tolerability and Pharmacokinetic and Pharmacodynamic Properties of Lu AF82422 in Healthy Non-Japanese and Japanese Subjects and in Patients With Parkinson's Disease
Phase of Trial: Phase I
Latest Information Update: 09 Sep 2019
Price : $35 *
At a glance
- Drugs Lu AF82422 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Lundbeck A/S
- 05 Sep 2019 Planned End Date changed from 1 Mar 2020 to 1 Jun 2020.
- 05 Sep 2019 Planned primary completion date changed from 1 Oct 2019 to 1 Jan 2020.
- 10 Aug 2018 New trial record